Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The sponsors had no input into the content of articles, which were independently prepared by the authors and have undergone the journals standard peer-review process
Published Phase 2 data shows: Dose Group Discontinuation Due to AE Placebo 0% 1 mg 2.9% 4 mg (escalated) 5.7% 8 mg (escalated) 5.0% 12 mg (escalated) 8.3% For context, discontinuation rates in semaglutide 2.4 mg trials (STEP program) were approximately 7%, and tirzepatide 15 mg trials (SURMOUNT) reported approximately 6-7%
pregnancy or breastfeeding
By activating the GLP-1 receptors in the body, it helps increase insulin release, decrease glucagon (a hormone that raises blood sugar), and slow gastric emptying
March 2026 (Expected) An FDA decision is anticipated for Eli Lilly's oral GLP-1 medication or forglipron
A peer review file is available
US$ 24.57
US$ 24.97
US$ 28.89
US$ 23.53
